Primary Biliary Cholangitis

  1. What Is Primary Biliary Cholangitis
  2. Pathogenesis and Immune Mechanisms
  3. Clinical Presentation
  4. Diagnosis
  5. Biochemical Markers and Risk Stratification
  6. Treatment — Ursodeoxycholic Acid (UDCA)
  7. Treatment — Second-Line Therapies
  8. Management of Complications
  9. PBC-Specific Cancer Risks
  10. PBC Overlap Syndromes
  11. Liver Transplantation in PBC
  12. Research Papers
  13. Connections
  14. Featured Videos

What Is Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is a chronic, progressive, autoimmune cholestatic liver disease in which the body's own immune system destroys small and medium-sized intrahepatic bile ducts — specifically the interlobular bile ducts and septal bile ducts that drain bile from liver cells into the larger bile duct system. As these tiny ducts are progressively damaged and lost, bile backs up inside the liver, causing a state known as cholestasis. Over years to decades, this toxic bile accumulation triggers inflammation, fibrosis, and, in untreated or treatment-refractory patients, eventual biliary cirrhosis and liver failure.

The disease was formerly called primary biliary cirrhosis — a name that carried significant social stigma because the word "cirrhosis" is publicly associated with alcoholism. In 2015, an international consortium of patient groups and hepatologists formally renamed it primary biliary cholangitis to more accurately describe the disease (it is a cholangiopathy — a disease of bile ducts — that does not inevitably lead to cirrhosis, especially when treated early) and to reduce the burden of stigma on patients.

PBC has the strongest female predominance of any autoimmune disease: approximately 90–95% of patients are women, and most are diagnosed between ages 40 and 60. Prevalence is approximately 1 in 1,000 women over age 40. Global prevalence is rising — partly due to improved detection via routine laboratory testing and partly due to true incidence increases whose cause is not fully understood. Geographic clustering was first recognized in Yorkshire, England, and later confirmed worldwide, pointing to shared environmental exposures (water sources, industrial chemicals, microbial agents) that interact with genetic susceptibility.

Without treatment, the natural history of PBC spans decades: an asymptomatic phase of gradually rising alkaline phosphatase, followed by symptomatic cholestasis (fatigue, pruritus), progressive fibrosis, and ultimately cirrhosis with its complications (portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma). First-line treatment with ursodeoxycholic acid (UDCA), introduced in the 1990s, transformed PBC from a disease with median survival of 10–15 years to one where most UDCA-responders achieve near-normal life expectancy.

Back to Table of Contents

Pathogenesis and Immune Mechanisms

The hallmark laboratory finding of PBC is the anti-mitochondrial antibody (AMA), present in approximately 95% of patients. AMAs in PBC specifically target the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), a mitochondrial enzyme that plays a central role in cellular energy metabolism. The AMA titer correlates poorly with disease severity but is highly specific for PBC — a positive AMA at titer ≥1:40 has greater than 95% specificity for the disease.

The central mystery of PBC is why this autoimmune attack targets biliary epithelial cells (cholangiocytes) specifically, even though PDC-E2 is present in virtually every cell of the body. The answer lies in a unique property of cholangiocytes: unlike other cells, they abnormally display intact PDC-E2 on their cell surface during apoptosis (programmed cell death), rather than modifying it as other cells do. This exposes the PDC-E2 antigen to circulating AMAs and to cytotoxic T lymphocytes. CD4+ helper T cells and CD8+ cytotoxic T cells infiltrate the bile ducts and directly destroy the biliary epithelium — a process visible on liver biopsy as the classic florid bile duct lesion (also called granulomatous cholangitis).

The molecular mimicry hypothesis proposes that the initial immune trigger comes from outside the body. Proteins from certain bacteria — most notably Novosphingobium aromaticivorans (a soil bacterium) and Escherichia coli (a common gut and urinary tract pathogen) — share structural similarities with PDC-E2. In genetically susceptible individuals, an immune response mounted against these bacteria may cross-react with the body's own PDC-E2, breaking immune tolerance and initiating the autoimmune cascade. This explains the epidemiological observation that urinary tract infections, especially recurrent E. coli UTIs, are significantly more common in PBC patients before diagnosis than in controls.

Genetic susceptibility contributes substantially. HLA haplotypes DRB1*08 and DQB1*04 are associated with PBC susceptibility across multiple ethnic groups. Genome-wide association studies have identified additional risk variants in genes encoding immune signaling molecules: IL12A and IL12RB2 (interleukin-12 signaling, which drives Th1 immunity), STAT4 (a transcription factor downstream of IL-12), and IRF5 (an interferon regulatory factor). Higher rates of X-chromosome monosomy (45,X mosaicism) have been found in women with PBC compared to controls, suggesting that X-chromosome gene dosage or X-inactivation abnormalities may contribute to loss of self-tolerance.

Environmental triggers implicated in epidemiological studies include cigarette smoking, hair dye use, nail polish chemicals (specifically certain organic solvents and halogenated compounds), and reproductive hormone exposures. The convergence of genetic vulnerability with microbial and chemical environmental triggers likely explains why PBC occurs in geographic clusters and in certain occupational groups.

Back to Table of Contents

Clinical Presentation

The clinical picture of PBC has changed dramatically over the past three decades. Because alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) are now routinely included in standard metabolic panels, the majority of new PBC diagnoses are made in asymptomatic patients who are found incidentally to have elevated cholestatic liver enzymes. Confirmatory AMA testing then establishes the diagnosis before any symptoms develop. This shift toward early detection has substantially improved outcomes.

Fatigue is the most common symptom, affecting 40–80% of PBC patients. Importantly, the fatigue of PBC is disproportionate to disease severity — patients with mild biochemical disease can be profoundly fatigued, while patients with advanced fibrosis may feel relatively well. Mechanisms are incompletely understood but involve both central (brain) and peripheral (muscle) components, including altered central neurotransmission (reduced serotonergic tone), autonomic dysfunction, and mitochondrial dysfunction in skeletal muscle. No pharmacotherapy is reliably effective. Fatigue that fails to improve on UDCA is one of the most challenging aspects of PBC to manage.

Pruritus (itch) is the most distinctive and often most distressing symptom of PBC. It affects 20–70% of patients during the course of disease. The itch of cholestasis is mediated by multiple pathways: accumulation of bile salts in skin, elevated levels of lysophosphatidic acid (LPA, a potent pruritogen generated by autotaxin from lysophosphatidylcholine), and activation of endogenous opioid receptors in the central nervous system. Cholestatic pruritus characteristically worsens at night, affects the palms and soles first, and can precede the appearance of jaundice by months or even years. It does not necessarily correlate with bilirubin levels. Intractable pruritus — pruritus unresponsive to all medical therapies — is itself a recognized indication for liver transplantation, independent of synthetic liver function.

Jaundice (yellowing of skin and eyes due to elevated bilirubin) is a late finding in PBC and generally indicates advanced disease, progressive loss of bile duct function, or transition toward biliary cirrhosis. Elevated bilirubin at any point in the disease course carries the strongest prognostic weight of any single laboratory marker.

Sicca symptoms — dry eyes (xerophthalmia) and dry mouth (xerostomia) — occur in 50–70% of PBC patients, reflecting the frequent overlap with Sjogren's syndrome (a separate autoimmune condition targeting exocrine glands). These symptoms are managed with artificial tears, lubricating eye drops, saliva substitutes, and sometimes pilocarpine or cevimeline to stimulate residual secretion.

Other autoimmune conditions co-occur at increased frequency: autoimmune thyroid disease (Hashimoto's thyroiditis or Graves' disease) affects 15–25% of PBC patients. Raynaud's phenomenon (episodic vasospasm of fingers and toes triggered by cold), CREST syndrome (a form of limited systemic sclerosis), and celiac disease are also seen more commonly in PBC than in the general population. Routine screening for thyroid disease and celiac disease is recommended at PBC diagnosis.

Back to Table of Contents

Diagnosis

PBC is diagnosed when two of the following three criteria are met — liver biopsy is not required when both serological and biochemical criteria are satisfied:

  1. Positive AMA at titer ≥1:40 by immunofluorescence, or positive AMA-M2 (anti-PDC-E2) by ELISA. This is present in approximately 95% of PBC patients and is highly specific (>95%) for the disease.
  2. Cholestatic liver biochemistry pattern: elevated alkaline phosphatase (ALP) and/or GGT, disproportionate to any elevation of alanine aminotransferase (ALT) or aspartate aminotransferase (AST). The pattern is specifically cholestatic — bile duct dysfunction rather than hepatocellular injury.
  3. Compatible liver biopsy: the pathognomonic finding is the florid bile duct lesion (granulomatous cholangitis — lymphoplasmacytic infiltration surrounding and destroying a bile duct, often with accompanying non-caseating granulomas). Biopsy is most useful when serology is negative or the diagnosis is uncertain.

AMA-negative PBC accounts for approximately 5% of cases. In these patients, specific antinuclear antibody (ANA) subtypes serve as diagnostic alternatives: anti-sp100 (speckled nuclear body pattern) and anti-gp210 (nuclear envelope/rim pattern). Anti-gp210 positivity is particularly important because it predicts a more aggressive disease course with higher risk of progression to cirrhosis. AMA-negative PBC is otherwise clinically, histologically, and prognostically indistinguishable from AMA-positive disease.

When biopsy is performed, disease stage is assigned using the Ludwig staging system: Stage I (portal stage — inflammation confined to portal tracts with bile duct damage), Stage II (periportal stage — interface hepatitis, periportal fibrosis), Stage III (septal stage — bridging fibrosis connecting portal tracts), Stage IV (cirrhosis). More recent systems (Scheuer, Nakanuma) are also in use. Biopsy has become less commonly performed as non-invasive assessments (elastography, biochemical markers) have improved.

The differential diagnosis of an elevated ALP with positive AMA is almost exclusively PBC. Other conditions causing elevated ALP include primary sclerosing cholangitis (PSC; negative AMA, characteristic cholangiographic findings on MRCP), autoimmune hepatitis (negative AMA, typically elevated transaminases, positive ANA/ASMA/LKM1), drug-induced cholestasis, biliary obstruction (gallstones, malignancy — visualized on imaging), granulomatous liver disease (sarcoidosis — negative AMA), and bone disease (isolated ALP elevation from bone isoenzyme — confirmed by normal GGT).

Back to Table of Contents

Biochemical Markers and Risk Stratification

Risk stratification in PBC — identifying which patients will progress rapidly versus those who will remain stable — is crucial for treatment decisions. Because UDCA fails to achieve adequate biochemical response in 40–60% of patients, validated response criteria help identify non-responders who need second-line therapy early.

Alkaline phosphatase (ALP) is the primary marker of disease activity and treatment response. ALP elevation reflects the degree of bile duct inflammation and cholestasis. The degree of ALP reduction on UDCA therapy is the most commonly used measure of biochemical response.

Bilirubin carries the strongest prognostic weight of any single laboratory value. Even modest bilirubin elevations above normal predict significantly worse transplant-free survival. The original Mayo Risk Score — still in clinical use — is based primarily on bilirubin, albumin, prothrombin time, age, and presence of edema.

Validated biochemical response criteria assessed after 12 months of UDCA therapy include:

Composite risk scores that integrate multiple markers at 1 year of UDCA provide more accurate individual prognosis:

High-risk features at any stage include: younger age at diagnosis (more years of progressive disease), male sex (male PBC tends to present at more advanced stage and has worse prognosis), positive anti-gp210 antibody, elevated bilirubin, low albumin, thrombocytopenia (reflecting portal hypertension and hypersplenism), advanced histological stage on biopsy, and presence of overlap features (autoimmune hepatitis components).

Back to Table of Contents

Treatment — Ursodeoxycholic Acid (UDCA)

Ursodeoxycholic acid (UDCA) — also known as ursodiol — has been the cornerstone of PBC treatment since its FDA approval for this indication in 1997. It is a naturally occurring hydrophilic (water-soluble, non-toxic) bile acid that constitutes only a small fraction of normal human bile but is abundant in bear bile (the source of its name: ursus = bear in Latin). When taken at therapeutic doses of 13–15 mg/kg/day, UDCA substantially alters the composition of the bile acid pool, displacing the more toxic hydrophobic bile acids that accumulate in cholestasis.

UDCA works through multiple complementary mechanisms:

In large, long-term trials and pooled analyses, UDCA has been shown to improve biochemical markers (ALP, GGT, bilirubin, ALT), slow histological progression (delay fibrosis staging), delay time to liver transplantation, and improve transplant-free survival — particularly in patients who achieve biochemical response. UDCA is very well tolerated; the most common side effects are mild weight gain and, in some patients, diarrhea or loose stools (especially at higher doses).

The critical limitation of UDCA is that 40–60% of patients do not achieve adequate biochemical response by Paris, Toronto, or GLOBE criteria after 12–24 months of therapy. These non-responders continue to have active cholestasis, progressive biliary injury, and worse long-term outcomes. They constitute the primary target population for second-line therapies.

Back to Table of Contents

Treatment — Second-Line Therapies

For patients who fail to achieve adequate biochemical response to UDCA (approximately 40–60% of PBC patients), or who are intolerant of UDCA, several second-line therapies are now available or in late-stage clinical development.

Obeticholic acid (OCA; brand name Ocaliva) is a semi-synthetic derivative of chenodeoxycholic acid and a potent agonist of the farnesoid X receptor (FXR), a nuclear receptor that is the master regulator of bile acid synthesis and transport. FDA approval was granted in 2016, making OCA the first new PBC treatment in nearly 20 years. The pivotal POISE trial demonstrated that OCA (5–10 mg/day) added to UDCA significantly reduced ALP and bilirubin compared to UDCA alone. The starting dose is 5 mg/day, titrated to 10 mg/day at 3 months if tolerated.

The major side effect of OCA is dose-dependent pruritus, which occurs in 56–68% of treated patients and can be severe enough to require dose reduction or discontinuation — particularly problematic given that pruritus is already a major symptom of PBC itself. More critically, the FDA issued a black box warning in 2021 prohibiting OCA use in patients with decompensated cirrhosis (Child-Pugh B or C) or with a history of decompensation, after post-marketing reports of fatal or serious hepatic decompensation in such patients who received higher-than-recommended doses.

Fibrates (PPAR-alpha agonists) represent a powerful and increasingly adopted second-line option, particularly outside the United States. Bezafibrate (not commercially available in the US) was evaluated in the landmark BEZURSO trial, which randomized PBC patients with inadequate UDCA response to bezafibrate 400 mg/day plus UDCA versus UDCA plus placebo. The combination achieved ALP normalization in 67% of patients versus 2% in the UDCA-only group at 2 years, and also significantly reduced pruritus scores and fatigue — a notable advantage over OCA. Fenofibrate (available in the US) shows similar biochemical efficacy in smaller trials and is increasingly used off-label in UDCA non-responders. European guidelines now recommend fibrates as a second-line option alongside OCA.

Elafibranor (PPAR-alpha/delta dual agonist) received FDA Breakthrough Therapy designation for PBC and was evaluated in the ELATIVE trial (2023), which demonstrated significant ALP reduction and biochemical response in UDCA-inadequate patients. A key advantage is a favorable pruritus profile — elafibranor did not worsen pruritus in clinical trials, in contrast to OCA.

Seladelpar (PPAR-delta selective agonist) demonstrated efficacy in the RESPONSE trial, achieving biochemical normalization in a significant proportion of UDCA inadequate responders. It also showed anti-pruritic properties, potentially making it a particularly attractive option for patients with prominent itch.

Linerixibat is an ileal bile acid transporter (IBAT) inhibitor that prevents reabsorption of bile acids from the gut, reducing the overall bile acid load in the body. It is specifically being developed for the management of cholestatic pruritus in PBC rather than for biochemical disease control.

Back to Table of Contents

Management of Complications

Managing the complications of PBC requires addressing both disease-specific symptoms and the general complications of advanced liver disease.

Pruritus is managed in a step-up fashion:

  1. Cholestyramine (4 g sachets, taken 30 minutes before and 4–6 hours after other medications to avoid drug absorption interference): a bile acid sequestrant that binds bile acids in the gut and reduces their reabsorption. Must be taken at least 2–4 hours away from UDCA and other medications. Efficacy is modest and tolerability is limited by constipation and palatability.
  2. Rifampicin (150 mg twice daily, increasing to 300 mg twice daily): an antibiotic with potent bile acid metabolism effects via PXR receptor activation, leading to increased hydroxylation and excretion of toxic bile acid species. Highly effective for cholestatic pruritus in controlled trials. Requires monitoring of liver function tests (can rarely cause drug-induced liver injury). Risk of drug-drug interactions (rifampicin is a strong CYP450 inducer).
  3. Opioid antagonists (naltrexone 12.5–50 mg/day orally, or naloxone IV in acute settings): cholestatic pruritus has a significant endogenous opioid-mediated component. Opioid antagonists effectively reduce itch but can cause an opioid withdrawal-like reaction (nausea, vomiting, abdominal pain, sleep disruption) in the first days of use; starting at very low doses and titrating slowly reduces this risk.
  4. Sertraline (75–100 mg/day): an SSRI antidepressant with anti-pruritic properties in PBC, possibly via modulation of central opioid and serotonin pathways. Well tolerated and also beneficial for the depression and anxiety that commonly co-occur with chronic pruritus.
  5. Intractable pruritus (refractory to all above): options include plasmapheresis (removes circulating pruritogens including LPA and bile acids), nasobiliary drainage (mechanical drainage of bile; temporary effect), ultraviolet B (UVB) phototherapy, and — definitively — liver transplantation. Intractable pruritus alone, in the absence of other standard transplant indications, is accepted as a valid transplant indication given the profound impact on quality of life.

Fatigue in PBC has no proven pharmacotherapy. Before accepting PBC-related fatigue, it is critical to exclude and treat potentially reversible contributors: anemia (iron deficiency from portal hypertensive enteropathy; B12/folate deficiency), hypothyroidism (co-occurs in 15–25%), sleep disorders (obstructive sleep apnea, restless legs syndrome, insomnia worsened by pruritus), depression, and anemia. Modafinil (a wakefulness-promoting agent) showed initial promise in small trials but has not been confirmed in larger controlled studies. Exercise programs, cognitive behavioral therapy, and sleep hygiene optimization may provide modest benefit.

Fat-soluble vitamin deficiencies occur in advanced PBC because bile acid deficiency in the gut impairs the absorption of fat-soluble vitamins A, D, E, and K. Vitamin D deficiency is particularly common and, combined with calcium malabsorption, accelerates bone loss. All PBC patients should receive: DEXA scan at diagnosis to assess bone density; oral vitamin D3 supplementation (often 1,000–2,000 IU/day or more); calcium supplementation; and bisphosphonates (alendronate, risedronate, zoledronic acid) for established osteoporosis. Vitamins A, E, and K (as phytonadione) should be supplemented if deficient.

Hypercholesterolemia is a paradox in PBC: cholestasis causes elevated total cholesterol (especially HDL) due to impaired cholesterol excretion via bile. Yet most large studies have found that PBC patients do not have a significantly increased risk of cardiovascular events compared to the general population, possibly because the cholesterol elevation is predominantly in the protective HDL fraction and because a unique lipoprotein particle called lipoprotein-X is elevated (it is not atherogenic). Statins can be used safely in PBC when cardiovascular risk assessment indicates their need and liver synthetic function is preserved.

Portal hypertension and cirrhosis complications (variceal bleeding, ascites, hepatic encephalopathy, spontaneous bacterial peritonitis) are managed using standard evidence-based protocols: non-selective beta-blockers or endoscopic band ligation for varices, diuretics and paracentesis for ascites, lactulose and rifaximin for hepatic encephalopathy.

Back to Table of Contents

PBC-Specific Cancer Risks

Patients with PBC carry elevated risks for certain malignancies that require targeted surveillance strategies.

Hepatocellular carcinoma (HCC) is the most clinically important cancer risk in PBC. While the absolute risk is lower than in cirrhosis from viral hepatitis (HCV, HBV), patients with PBC-related cirrhosis face an annual HCC incidence of approximately 1–2%, which clearly exceeds the threshold (0.2% per year) at which semi-annual ultrasound surveillance is cost-effective and guideline-recommended. Standard surveillance consists of liver ultrasound with or without alpha-fetoprotein (AFP) every 6 months in all PBC patients with established cirrhosis (Ludwig Stage IV) or advanced fibrosis. HCC in PBC can occasionally occur even in pre-cirrhotic fibrosis, particularly in male patients, though this is less well-established.

Compared to viral hepatitis cirrhosis, HCC in PBC tends to occur in older patients and may present at a smaller size due to the more vigilant monitoring typical of specialist hepatology follow-up. Outcomes are generally favorable when HCC is detected at an early stage within Milan criteria (single nodule ≤5 cm, or up to 3 nodules none exceeding 3 cm), where curative treatments (resection, ablation, or liver transplantation) remain feasible.

Cholangiocarcinoma (CCA) occurs at modestly elevated rates in PBC compared to the general population, but the risk is substantially lower than in primary sclerosing cholangitis (PSC), where CCA is a major cause of death. Routine CCA surveillance beyond standard HCC surveillance is not currently recommended in PBC without additional risk factors. New dominant strictures on imaging in PBC patients should prompt evaluation to exclude CCA.

Breast cancer has been reported at elevated rates in PBC patients in some epidemiological studies, but evidence is inconsistent across cohorts. Current guidelines do not recommend additional breast cancer screening beyond standard age-appropriate mammography recommendations in PBC. Patients and clinicians should be aware of this possible association and maintain standard screening practices.

Back to Table of Contents

PBC Overlap Syndromes

PBC does not exist in immunological isolation. A meaningful proportion of PBC patients exhibit features of other autoimmune liver or systemic autoimmune diseases — so-called overlap syndromes — which can complicate diagnosis and require modified treatment approaches.

PBC-AIH overlap (autoimmune hepatitis overlap) is the most clinically significant overlap, affecting approximately 8–10% of PBC patients. It is diagnosed when a patient meets both PBC criteria and the Paris criteria for AIH: (1) elevated ALT ≥5× ULN, (2) elevated IgG ≥2× ULN or positive smooth muscle antibody (SMA), and (3) liver biopsy showing moderate-to-severe periportal or periseptal lymphocyte-plasma cell interface hepatitis. The clinical behavior is more aggressive than either disease alone. Treatment with UDCA alone is often insufficient — immunosuppression with prednisone (typically 0.5–1 mg/kg/day with gradual taper) plus azathioprine (1–2 mg/kg/day as maintenance) is added to UDCA when AIH features are prominent. Response to immunosuppression is generally good but must be monitored carefully for side effects.

Sjogren's syndrome overlap is the most common systemic overlap in PBC. As many as 50–70% of PBC patients have sicca symptoms (dry eyes, dry mouth), and formal Sjogren's syndrome criteria are met in approximately 20–30%. The presence of anti-SSA (Ro) and anti-SSB (La) antibodies supports a Sjogren's diagnosis in this context. Sicca symptoms in PBC are managed symptomatically with artificial tears, lubricating gels, saliva substitutes, and secretagogues (pilocarpine 5 mg three times daily, cevimeline). The presence of Sjogren's does not change PBC treatment but requires its own management.

Systemic sclerosis and CREST syndrome overlap occurs in approximately 3–10% of PBC patients, most often with limited cutaneous systemic sclerosis (lcSSc, formerly CREST). Patients with both PBC and systemic sclerosis have higher rates of pulmonary arterial hypertension, a complication that requires specific screening (echocardiography) and treatment (endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues).

Thyroid autoimmunity (Hashimoto's thyroiditis, Graves' disease) co-occurs in 15–25% of PBC patients and should be screened for routinely at diagnosis with TSH and anti-thyroid peroxidase antibodies. Hypothyroidism, if present and untreated, significantly worsens PBC-associated fatigue and may be mistaken for disease progression.

Celiac disease is found in 2–6% of PBC patients — a rate 3–5 times higher than the general population. Routine screening with anti-tissue transglutaminase IgA and serum IgA at diagnosis is recommended. Diagnosis of celiac disease in PBC patients is important because a gluten-free diet may improve both gastrointestinal symptoms and hepatic biochemistry, and undiagnosed celiac disease worsens fat-soluble vitamin deficiencies and osteoporosis.

Back to Table of Contents

Liver Transplantation in PBC

Liver transplantation (LT) remains the definitive treatment for end-stage PBC and represents one of the great success stories of modern hepatology. PBC is one of the best indications for liver transplantation in terms of post-transplant outcomes: 5-year patient survival is 85–90%, and 10-year survival exceeds 70% in most large series — outcomes substantially better than transplantation for other common indications such as alcoholic liver disease or HCC.

Standard indications for listing include:

Recurrent PBC after transplantation occurs in 15–25% of recipients over 10 years. Recurrence is histologically diagnosed on protocol biopsy (the classic florid bile duct lesion reappears) and is typically mild, with slow progression. AMAs do not disappear after transplant but their presence does not predict recurrence or outcome. UDCA is usually prescribed post-transplant to reduce the risk or slow the progression of recurrent PBC. Immunosuppression regimens using tacrolimus (rather than ciclosporin) have been associated with slightly higher rates of recurrence in some series, though this remains debated.

The excellent long-term prognosis after liver transplantation for PBC underscores the importance of timely referral to a transplant center when patients with PBC show signs of decompensation, rising bilirubin, worsening synthetic function, or intractable symptoms. Early referral before patients are critically ill is associated with better surgical outcomes and shorter waiting times.

Back to Table of Contents

Research Papers

The following PubMed searches cover the key clinical and scientific literature on Primary Biliary Cholangitis:

  1. UDCA PBC randomized controlled trials and long-term outcomes
  2. Obeticholic acid POISE trial PBC — FXR agonist second-line therapy
  3. Bezafibrate BEZURSO trial PBC — PPAR-alpha agonist combination therapy
  4. Elafibranor ELATIVE trial PBC — PPAR-alpha/delta dual agonist
  5. PBC cholestatic pruritus — rifampicin, sertraline, opioid antagonist treatment
  6. Anti-mitochondrial antibody AMA PDC-E2 pathogenesis molecular mimicry PBC
  7. PBC diagnosis criteria AMA cholestasis — EASL AASLD guidelines
  8. PBC hepatocellular carcinoma surveillance risk in cirrhosis
  9. PBC liver transplantation outcomes post-transplant survival and recurrence
  10. PBC fatigue pathogenesis and management — central autonomic peripheral mechanisms
  11. GLOBE score and UK-PBC score — biochemical response prediction and risk stratification
  12. PBC-AIH overlap syndrome — Paris criteria, diagnosis, and combined treatment

Back to Table of Contents

Connections

Back to Table of Contents